You're right on the tax impact but not necessarily the R&D/valuation. Yes, R&D of course drives growth but it's also possible that excessive R&D could be translating into inefficiency.
Valuation theory isn't an exact science, many people/instos wouldn't buy CSL for instance as the PE is too high or the dividend yield is too low. No one is suggesting R&D should be cut totally but it should perhaps be more efficiently run. Would be interesting to know what the opportunity cost of either scenario would be according to management.
You're right on the tax impact but not necessarily the...
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.21 |
Change
0.050(0.02%) |
Mkt cap ! $142.6B | |||
| Open | High | Low | Value | Volume |
| $296.30 | $298.20 | $295.00 | $229.6M | 780.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248 | $295.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $295.21 | 42 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |